Pfizer Inc. $PFE Holdings Trimmed by M Holdings Securities Inc.

M Holdings Securities Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 2.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,018 shares of the biopharmaceutical company’s stock after selling 1,798 shares during the quarter. M Holdings Securities Inc.’s holdings in Pfizer were worth $2,002,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of PFE. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. Freedom Investment Management Inc. boosted its position in shares of Pfizer by 67.5% in the 4th quarter. Freedom Investment Management Inc. now owns 31,737 shares of the biopharmaceutical company’s stock valued at $842,000 after purchasing an additional 12,792 shares during the period. Capital International Inc. CA boosted its position in shares of Pfizer by 10.6% in the 4th quarter. Capital International Inc. CA now owns 349,653 shares of the biopharmaceutical company’s stock valued at $9,276,000 after purchasing an additional 33,489 shares during the period. Finally, Ossiam boosted its position in shares of Pfizer by 44.2% in the 4th quarter. Ossiam now owns 265,695 shares of the biopharmaceutical company’s stock valued at $7,049,000 after purchasing an additional 81,496 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

PFE opened at $25.16 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The business has a 50-day moving average of $24.60 and a 200-day moving average of $24.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $143.05 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business earned $0.60 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PFE shares. The Goldman Sachs Group increased their price target on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. TD Cowen decreased their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research report on Tuesday, April 22nd. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.